619 related articles for article (PubMed ID: 23845225)
21. Expression of HER2/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary.
Karaferic A; Jovanovic D; Jelic S
J BUON; 2009; 14(4):635-9. PubMed ID: 20148455
[TBL] [Abstract][Full Text] [Related]
22. [Prognostic differentiation of ovarian carcinomas by immunohistochemical analysis of estrogen receptor expression].
Kieback DG; Press MF; McCamant SK; Atkinson EN; Möbus VJ; Runnebaum IB; Kreienberg R; Jones LA
Geburtshilfe Frauenheilkd; 1995 Apr; 55(4):189-94. PubMed ID: 7789706
[TBL] [Abstract][Full Text] [Related]
23. Outcome in serous ovarian cancer is not associated with LATS expression.
Montavon C; Stricker GR; Schoetzau A; Heinzelmann-Schwarz V; Jacob F; Fedier A
J Cancer Res Clin Oncol; 2019 Nov; 145(11):2737-2749. PubMed ID: 31586262
[TBL] [Abstract][Full Text] [Related]
24. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
[TBL] [Abstract][Full Text] [Related]
25. Prognostic analysis of ovarian cancer associated with endometriosis.
Kumar S; Munkarah A; Arabi H; Bandyopadhyay S; Semaan A; Hayek K; Garg G; Morris R; Ali-Fehmi R
Am J Obstet Gynecol; 2011 Jan; 204(1):63.e1-7. PubMed ID: 21074136
[TBL] [Abstract][Full Text] [Related]
26. Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma.
Matsuo K; Sheridan TB; Mabuchi S; Yoshino K; Hasegawa K; Studeman KD; Im DD; Rosenshein NB; Roman LD; Sood AK
Gynecol Oncol; 2014 Jun; 133(3):473-9. PubMed ID: 24674832
[TBL] [Abstract][Full Text] [Related]
27. Association of Hormone Receptor Expression with Survival in Ovarian Endometrioid Carcinoma: Biological Validation and Clinical Implications.
Rambau P; Kelemen LE; Steed H; Quan ML; Ghatage P; Köbel M
Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28264438
[TBL] [Abstract][Full Text] [Related]
28. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis.
Reid-Nicholson M; Iyengar P; Hummer AJ; Linkov I; Asher M; Soslow RA
Mod Pathol; 2006 Aug; 19(8):1091-100. PubMed ID: 16648864
[TBL] [Abstract][Full Text] [Related]
29. HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features.
Ota T; Gilks CB; Longacre T; Leung PC; Auersperg N
Reprod Sci; 2007 Sep; 14(6):605-14. PubMed ID: 17959889
[TBL] [Abstract][Full Text] [Related]
30. The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification.
Guan J; Xie L; Luo X; Yang B; Zhang H; Zhu Q; Chen X
J Gynecol Oncol; 2019 Jan; 30(1):e13. PubMed ID: 30479097
[TBL] [Abstract][Full Text] [Related]
31. Vascular endothelial growth factor (VEGF) and cyclooxygenase 2 (COX 2) immunostaining in ovarian cancer.
Whynott RM; Manahan P; Geisler JP
Eur J Gynaecol Oncol; 2016; 37(2):164-6. PubMed ID: 27172738
[TBL] [Abstract][Full Text] [Related]
32. A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging.
Skírnisdóttir I; Seidal T; Sorbe B
Int J Gynecol Cancer; 2004; 14(2):259-70. PubMed ID: 15086725
[TBL] [Abstract][Full Text] [Related]
33. CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer.
Chen X; Zhang J; Cheng W; Chang DY; Huang J; Wang X; Jia L; Rosen DG; Zhang W; Yang D; Gershenson DM; Sood AK; Bast RC; Liu J
Int J Gynecol Cancer; 2013 Jun; 23(5):815-22. PubMed ID: 23669443
[TBL] [Abstract][Full Text] [Related]
34. The CD44 receptor is a molecular predictor of survival in ovarian cancer.
Rodríguez-Rodríguez L; Sancho-Torres I; Mesonero C; Gibbon DG; Shih WJ; Zotalis G
Med Oncol; 2003; 20(3):255-63. PubMed ID: 14514975
[TBL] [Abstract][Full Text] [Related]
35. Favorable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinoma.
Borgoño CA; Fracchioli S; Yousef GM; Rigault de la Longrais IA; Luo LY; Soosaipillai A; Puopolo M; Grass L; Scorilas A; Diamandis EP; Katsaros D
Int J Cancer; 2003 Sep; 106(4):605-610. PubMed ID: 12845660
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer.
Salmena L; Shaw P; Fans I; McLaughlin ; Rosen B; Risch H; Mitchell C; Sun P; Narod SA; Kotsopoulos J
Eur J Gynaecol Oncol; 2015; 36(3):260-7. PubMed ID: 26189250
[TBL] [Abstract][Full Text] [Related]
37. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
Lax SF; Pizer ES; Ronnett BM; Kurman RJ
Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
[TBL] [Abstract][Full Text] [Related]
38. B7-H4 overexpression in ovarian tumors.
Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
[TBL] [Abstract][Full Text] [Related]
39. Low-Stage High-Grade Serous Ovarian Carcinomas: Support for an Extraovarian Origin.
Morency E; Leitao MM; Soslow RA
Int J Gynecol Pathol; 2016 May; 35(3):222-9. PubMed ID: 26630225
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of histological type in stage IV ovarian carcinoma: a retrospective analysis of 223 patients.
Mizuno M; Kajiyama H; Shibata K; Mizuno K; Kawai M; Nagasaka T; Kikkawa F
Br J Cancer; 2015 Apr; 112(8):1376-83. PubMed ID: 25867257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
